Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A low or intermediate grade well differentiated tumor with neuroendocrine differentiation that arises from the pancreas. It is characterized by the presence of a clinical syndrome that results from hormone hypersecretion.
Biomarker and diagnostic research for functional pancreatic neuroendocrine tumor has been reported in the published literature.
1 clinical trial registered. Interventions under study include drug therapy, other interventions, and procedural interventions. Pipeline includes 1 PHASE3. Research is primarily sponsored by academic and government institutions.
155 publications have been identified in PubMed for functional pancreatic neuroendocrine tumor. Research spans Basic Science / Preclinical (37%), Review / Meta-Analysis (22%), and Diagnostic / Biomarker (11%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 57 |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 11:57 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries | 34 | 22% |
Testing and diagnosis research | 17 | 11% |
Clinical study results | 15 | 10% |
Patient case studies | 10 | 6% |
Disease patterns and progression | 10 | 6% |
New treatment approaches | 9 | 6% |
Other research | 3 | 2% |
Cui M (2026). [PMID: 41381181](https://pubmed.ncbi.nlm.nih.gov/41381181/). *Gut*. [Basic Science / Preclinical]
Cole Y (2026). [PMID: 41518596](https://pubmed.ncbi.nlm.nih.gov/41518596/). *J Clin Endocrinol Metab*. [Case Report / Case Series]
Zhang S (2026). [PMID: 41850238](https://pubmed.ncbi.nlm.nih.gov/41850238/). *Cell Rep Med*. [Basic Science / Preclinical]
Nakano A (2026). [PMID: 41568565](https://pubmed.ncbi.nlm.nih.gov/41568565/). *Endocr Relat Cancer*. [Epidemiology / Natural History]
Li K (2026). [PMID: 41490917](https://pubmed.ncbi.nlm.nih.gov/41490917/). *International journal of biological macromolecules*. [Basic Science / Preclinical]
Partelli S (2026). [PMID: 41856794](https://pubmed.ncbi.nlm.nih.gov/41856794/). *Journal of neuroendocrinology*. [Basic Science / Preclinical]
Jayaprakash V (2026). [PMID: 31869077](https://pubmed.ncbi.nlm.nih.gov/31869077/). *Unknown Journal*. [Case Report / Case Series]
Kasajima A (2026). [PMID: 41483302](https://pubmed.ncbi.nlm.nih.gov/41483302/). *Virchows Archiv : an international journal of pathology*. [Diagnostic / Biomarker]
Kunutsor SK (2026). [PMID: 41351656](https://pubmed.ncbi.nlm.nih.gov/41351656/). *Drugs*. [Basic Science / Preclinical]
Wang X (2026). [PMID: 41582215](https://pubmed.ncbi.nlm.nih.gov/41582215/). *Signal Transduct Target Ther*. [Review / Meta-Analysis]
AI-curated news mentioning functional pancreatic neuroendocrine tumor
Updated Jun 8, 2026
Recent research highlights pancreatic neuroendocrine tumors as part of the tumor spectrum associated with Lynch syndrome, indicating a broader impact of mismatch repair deficiency. This discovery could influence future screening and treatment strategies for affected patients.
A recent case report details the occurrence of metachronous primary pancreatic neuroendocrine tumor alongside adenocarcinoma. This study contributes to the understanding of pancreatic tumors and their potential interactions.